Clinical trial
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management…
NCT00216684 · Janssen Pharmaceutical K.K., Industry · Completed
Key facts
| NCT number | NCT00216684 |
|---|---|
| Title | Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics |
| Official title | An Open Label Study to Confirm the Effectiveness, and Safety of Fentanyl Transdermal Matrix Patch in Japanese Patients With Chronic Intractable Pain Who Has Prior Therapy of Codeine, Morphine Hydrochloride, or Fentanyl Injectable Preparations. |
| Lead sponsor | Janssen Pharmaceutical K.K., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Intractable |
| Intervention type | Drug |
| Interventions | fentanyl |
| Enrollment | 139 |
| Start date | May 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 1, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: